Germany
Spain
Japan
United States
This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy
Afatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC
Vera Hirsh, Eng-Huat Tan, Yi-Long Wu, Lecia V. Sequist, Caicun Zhou, Martin Schuler, Sarayut L. Geater, Tony Mok, Cheng-Ping Hu, Nobuyuki Yamamoto, Jifeng Feng, Kenneth O’Byrne, Shun Lu, Yunchao Huang, Martin Sebastian, Isamu Okamoto, Nicolas Dickgreber, Riyaz Shah, Michael Palmer, Angela Märten, Dan Massey, Carl Samuelsen, James Chih-Hsin Yang
Related Material
Learn more about the science behind this poster in the videos, papers and other materials below.
